Title |
Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial
|
---|---|
Published in |
Lancet Oncology, December 2011
|
DOI | 10.1016/s1470-2045(11)70300-x |
Pubmed ID | |
Authors |
Ralf Trappe, Stephan Oertel, Veronique Leblond, Peter Mollee, Monica Sender, Petra Reinke, Ruth Neuhaus, Hans Lehmkuhl, Heinz August Horst, Gilles Salles, Franck Morschhauser, Arnaud Jaccard, Thierry Lamy, Malte Leithäuser, Heiner Zimmermann, Ioannis Anagnostopoulos, Martine Raphael, Hanno Riess, Sylvain Choquet, for the German PTLD Study Group, the European PTLD Network |
Abstract |
Post-transplantation lymphoproliferative disorder (PTLD) develops in 1-10% of transplant recipients and can be Epstein-Barr virus (EBV) associated. To improve long-term efficacy after rituximab monotherapy and to avoid the toxic effects of CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisolone) chemotherapy seen in first-line treatment, we initiated a phase 2 trial to test whether the subsequent use of rituximab and CHOP would improve the outcome of patients with PTLD. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Japan | 1 | 50% |
United States | 1 | 50% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 2 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
United Kingdom | 2 | <1% |
Netherlands | 1 | <1% |
Germany | 1 | <1% |
Canada | 1 | <1% |
United States | 1 | <1% |
Unknown | 198 | 97% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 34 | 17% |
Other | 27 | 13% |
Student > Postgraduate | 22 | 11% |
Student > Master | 18 | 9% |
Student > Doctoral Student | 14 | 7% |
Other | 40 | 20% |
Unknown | 49 | 24% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 109 | 53% |
Agricultural and Biological Sciences | 12 | 6% |
Pharmacology, Toxicology and Pharmaceutical Science | 5 | 2% |
Immunology and Microbiology | 4 | 2% |
Biochemistry, Genetics and Molecular Biology | 4 | 2% |
Other | 13 | 6% |
Unknown | 57 | 28% |